Cases of CTCL disease progression or unmasking in previously undiagnosed patients who take TNFα inhibitors have been reported illustrating the potential critical role of TNFα in the immunologic control of MF and other types of CTCL [18,19]. The gene discussed is TNF; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.